Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910936 | 0.92 | PDK1 (0.41) | MKNK1MKNK2PDK1GRM2RECQL | |
| SCHEMBL2908090 | 0.92 | PDK1 (0.42) | PDK1GRM2RECQLUSP2ALDH1A1 | |
| SCHEMBL2905903 | 0.88 | MKNK1 (0.52) | MKNK1MKNK2CCNE1CDK2PDK1 | |
| SCHEMBL3205165 | 0.86 | NPC1 (0.43) | PDK1GRM2USP2ALDH1A1NPSR1 | |
| SCHEMBL2908816 | 0.85 | MKNK1 (0.38) | MKNK1MKNK2RECQLALDH1A1L3MBTL1 | |
| SCHEMBL3122799 | 0.84 | PDE4B (0.42) | GRM2USP2ALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL4193004 | 0.84 | PDE4A (0.52) | GRM2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2908802 | 0.83 | MKNK1 (0.53) | MKNK1MKNK2CCNE1CDK2PDK1 | |
| SCHEMBL3131249 | 0.83 | ALDH1A1 (0.45) | USP2ALDH1A1NPSR1L3MBTL1QPCT | |
| SCHEMBL4196553 | 0.81 | GRM2 (0.40) | GRM2SLC7A5PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007513957-A | — | — | 2007-05-31 | — | — | JP | claimed |
| EP-1692109-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | Memory Pharmaceuticals Corporation (US) | 2006-08-23 | — | — | EP | claimed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | claimed |
| WO-2005061458-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-07-07 | — | — | WO | claimed |
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1692109-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | Memory Pharmaceuticals Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
| WO-2005061458-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061458-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | MKNK1 4229/4885MKNK2 4117/4885CCNE1 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.